Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-15 · accession 0001104659-22-092204 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-08-17 | 2022-08-15 | SUPN | Khattar Jack A. | Pres, CEO, Dir | S - Sale+OE | $34.03 | -17.3K | 759.9K | -2% | -$588.8K |
| DM | 2022-08-17 | 2022-08-15 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $6.41 | +35.8K | 788.0K | +5% | +$229.3K |
| D | 2022-08-17 | 2022-08-15 | SUPN | Khattar Jack A. | Pres, CEO, Dir | M - OptEx | $0.00 | -46.6K | 45.4K | -51% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-15 | S | D | 17,302 | $34.03 | 759,901 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| 2 | Common | Common Stock | 2022-08-15 | M | D | 10,813 | $34.03 | 777,203 | D | — | — | (F2) Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| 3 | Common | Common Stock | 2022-08-15 | M | A | 46,575 | $0.00 | 788,016 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022. |
| 4 | Derivative | Stock Appreciation Right | 2022-08-15 | M | D | 46,575 | $0.00 | 45,425 | D | $7.90 · — to 2023-02-05 | 46,575 Common Stock | (F5) The stock appreciation right vested in four equal annual installments beginning on February 5, 2014. |